Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology

21-04-2024 | Ranibizumab | Retinal Disorders

Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity

Authors: Ya Tian, Zixin Fan, Xianlu Zeng, Zhen Yu, Xiaofeng Lu, Xinyu Zhao, Zhenquan Wu, Honghui He, Jian Zeng, Lei Zheng, Linlin Zhang, Victor S. M. C. Correa, Guishuang Ying, Shaochong Zhang, Guoming Zhang

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology

Login to get access

Abstract

Purpose

To evaluate the long-term cognitive function in children treated with intravitreal ranibizumab (IVR) for retinopathy of prematurity(ROP), and the impact of IVR on the growth and ocular development.

Methods

In this retrospective study, the premature children aged 4 to 9 years who received monotherapy of IVR (IVR group, n = 25) or monotherapy of laser photocoagulation (LP) (LP group, n = 33) for ROP, and the same age premature children with no ROP (Control group, n = 26) were enrolled from 2020 to 2022 in the pediatric fundus clinic of Shenzhen Eye Hospital. Main outcome measures were full-scale intelligence quotient (FSIQ) and index score using the Chinese version of the Wechsler intelligence scale for children-fourth edition (WISC-IV) and Wechsler preschool and primary scale of intelligence-fourth edition (WPPSI-IV). All children were examined and analyzed for growth and ocular development by recording the height, weight, head circumference, spherical equivalent (SE), best corrected visual acuity (BCVA) and axial length (AL).

Results

There were 17 children in IVR group, 17 in LP group, and 11 in Control group who received the WISC-IV assessment. There were no significant differences in FSIQ, verbal comprehension index, perceptual reasoning index, working memory index, processing speed index, general ability index and cognitive efficiency index among the three groups. There were 8 children in IVR group, 16 in LP group, and 15 in Control group who received the WPPSI-IV assessment. There were no significant differences in FSIQ, verbal comprehension index, visuospatial index, fluid reasoning index, working memory index, non-verbal index, general ability index and cognitive efficiency index among the three groups. There was no significant difference in BCVA among the three groups (P = 0.74), however, there is an increase for AL in IVR group when compared with LP group (22.60 ± 0.58 vs. 22.13 ± 0.84, P = 0.003), and the ROP patients of IVR group have a significant increase in the AL compared to the Control group(22.60 ± 0.58 vs. 22.03 ± 0.71, P < 0.0001).

Conclusions

Children with a history of IVR have a similar cognitive function outcomes compared to those with a history of LP or were premature without ROP. ROP children with a history of IVR has longer AL than those treated with LP.
Appendix
Available only for authorised users
Literature
1.
Norman M, Hellström A, Hallberg B, Wallin A, Gustafson P, Tornqvist K, Håkansson S, Holmström G (2019) prevalence of severe visual disability among preterm children with retinopathy of prematurity and association with adherence to best practice guidelines. JAMA Netw Open 2(1):e186801CrossRefPubMedPubMedCentral
2.
Bashinsky AL (2017) Retinopathy of prematurity. N C Med J 78(2):124–128PubMed
3.
Sen P, Wu WC, Chandra P, Vinekar A, Manchegowda PT, Bhende P (2020) Retinopathy of prematurity treatment: Asian perspectives. Eye (Lond) 34(4):632–642CrossRefPubMed
4.
Rattner A, Wang Y, Nathans J (2022) Signaling pathways in neurovascular development. Annu Rev Neurosci 45:87–108CrossRefPubMed
5.
Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37:694–701CrossRefPubMed
6.
Tawse KL, Jeng-Miller KW, Baumal CR (2016) Current practice patterns for treatment of retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imaging Retina 47(5):491–495CrossRefPubMed
7.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 37(10):1847–1858CrossRefPubMedPubMedCentral
8.
Lin CY, Hsu CH, Chang JH (2020) Taiwan premature infant follow-up network. Neurodevelopmental outcomes at 2 and 5 years of age in very-low-birth-weight preterm infants born between 2002 and 2009: a prospective cohort study in Taiwan. Pediatr Neonatol 61(1):36–44CrossRefPubMed
9.
Zhang H (2009) The revision of WISC-IV Chinese version. Psychol Sci 32:1177–1179
10.
Zhu Z, Chang S, Cheng Y, Qi Q, Li S, Elhoumed M, Yan H, Dibley MJ, Fawzi WW, Zeng L, Sudfeld CR (2019) Early life cognitive development trajectories and intelligence quotient in middle childhood and early adolescence in rural western China. Sci Rep 9:18315CrossRefPubMedPubMedCentral
11.
Rapuc S, Pierrat V, Marchand-Martin L, Benhammou V, Kaminski M, Ancel PY, Twilhaar ES (2023) The interrelatedness of cognitive abilities in very preterm and full-term born children at 5.5 years of age: a psychometric network analysis approach. J Child Psychol Psychiatry 65(1):18–30CrossRefPubMed
12.
Tan H, Blasco P, Lewis T, Ostmo S, Chiang MF, Campbell JP (2021) Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity. Surv Ophthalmol 66(5):877–891CrossRefPubMedPubMedCentral
13.
Diggikar S, Gurumoorthy P, Trif P, Mudura D, Nagesh NK, Galis R, Vinekar A, Kramer BW (2023) Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: a systematic review and meta-analysis. Front Pediatr 11:1055813CrossRefPubMedPubMedCentral
14.
Kandasamy Y, Hartley L, Rudd D, Smith R (2017) The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol 101(1):21–24CrossRefPubMed
15.
16.
Seery CW, Betesh S, Guo S, Zarbin MA, Bhagat N, Wagner RS (2020) Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 57(6):351–362CrossRefPubMed
17.
Han W, Jiang L, Song X, Li T, Chen H, Cheng L (2021) VEGF modulates neurogenesis and microvascular remodeling in epileptogenesis after status epilepticus in immature rats. Front Neurol 12:808568CrossRefPubMedPubMedCentral
18.
De Andrade LM, Isenberg SJ (2019) Does general anesthesia or intravitreal injection affect neurodevelopment in children undergoing ophthalmic procedures? Curr Opin Ophthalmol 30(5):326–330CrossRefPubMed
19.
Natarajan G, Shankaran S (2016) Short- and long-term outcomes of moderate and late preterm infants. Am J Perinatol 33(3):305–317CrossRefPubMed
20.
Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC, Chen KJ, Wu WC (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20–30CrossRefPubMed
21.
Chen YC, Chen SN (2020) Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 104(5):691–696CrossRefPubMed
22.
Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, Phelps DL, DeMauro SB, Carlo WA, Gantz MG, Das A, Greenberg RG, Younge NE, Bliss JM, Seabrook R, Sánchez PJ, Wyckoff MH, Bell EF, Vohr BR, Higgins RD (2019) Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics 144(2):e20183537CrossRefPubMed
23.
Celik P, Ayranci Sucakli I, Kara C, Petricli IS, Kavurt S, Celik IH, Bas AY, Demirel N (2022) Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry? J Matern Fetal Neonatal Med 35(3):415–422CrossRefPubMed
24.
Cevik SG, Cevik MT, Perente I (2020) Ocular and systemic results of intravitreal bevacizumab injection in retinopathy of prematurity treatment. Beyoglu Eye J 5(2):73–80PubMedPubMedCentral
25.
Wu AL, Wu WC (2018) Anti-VEGF for ROP and pediatric retinal diseases. Asia Pac J Ophthalmol (Phila) 7(3):145–151PubMed
26.
Chou HD, Shih CP, Huang YS, Liu L, Lai CC, Chen KJ, Hwang YS, Wu WC (2022) Cognitive outcomes following intravitreal bevacizumab for retinopathy of prematurity: 4- to 6-year outcomes in a prospective cohort. Am J Ophthalmol 234:59–70CrossRefPubMed
27.
Chiang MC, Chen YT, Kang EY, Chen KJ, Wang NK, Liu L, Chen YP, Hwang YS, Lai CC, Wu WC (2023) Neurodevelopmental outcomes for retinopathy of prematurity: a taiwan premature infant follow-up network database study. Am J Ophthalmol 247:170–180CrossRefPubMed
28.
Murakami T, Sugiura Y, Okamoto F, Okamoto Y, Kato A, Hoshi S, Nagafuji M, Miyazono Y, Oshika T (2021) Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 259(9):2849–2855CrossRefPubMed
29.
Patel SN, Klufas MA (2019) Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. Eye Brain 23(11):25–35CrossRef
30.
Ghassemi F, Makateb A, Dastjani Farahani A, Mahmoudi A, Bazvand F (2022) Evaluation of neurodevelopmental outcomes in premature twins (Multigestations) with retinopathy of prematurity receiving anti-VEGF: a comparison study. J Ophthalmol 2022:5177401CrossRefPubMedPubMedCentral
31.
Marie A, Shin SM, Artemiy K, Bradley G, Irena T, Alison C (2021) Severe retinopathy of prematurity is not independently associated with worse neurodevelopmental outcomes in preterm neonates. Front Pediatr 9:679546CrossRef
Metadata
Title
Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity
Authors
Ya Tian
Zixin Fan
Xianlu Zeng
Zhen Yu
Xiaofeng Lu
Xinyu Zhao
Zhenquan Wu
Honghui He
Jian Zeng
Lei Zheng
Linlin Zhang
Victor S. M. C. Correa
Guishuang Ying
Shaochong Zhang
Guoming Zhang
Publication date
21-04-2024
Publisher
Springer Berlin Heidelberg
Keyword
Ranibizumab
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-024-06486-x